be0213 Search Results


anti mouse csf1r  (Bio X Cell)
96
Bio X Cell anti mouse csf1r
a-e. Flow cytometry analysis the proportions of CD4 + T and CD8 + T cells of MC38 (n=13/12), B16 (n=13/13), ID8 (n=11/12) and LLC (n=13/13) tumor microenvironments following control mAb or anti-hCD209 mAb treatment. f-i. Flow cytometry analysis of the proportions of CD4 + IFN-γ + T cells and CD8 + IFN-γ + T cells in the MC38, B16, ID8 and LLC tumor microenvironments following control mAb or anti-hCD209 mAb treatment. j-l. The expression levels of IFN-γ in the tumor culture supernatant and mouse serum of MC38, LLC, B16 and ID8 tumor-bearing mice after control mAb or anti-hCD209 mAb treatment were detected via ELISA. m. MC38 tumors were subcutaneously implanted into hCD209-KI mice, followed by anti-control, anti-hCD209 mAb, anti-control+αCD8 or anti-hCD209+αCD8 treatment (n=12/12/12/12), and tumor growth is shown ( m ). The depletion of CD8+ T cells is shown ( n ). o-q. Tumors were implanted as described in m , followed by treatment with anti-control, anti-hCD209 mAb, anti-control+αCSF1R or anti-hCD209+αCSF1R (n=12/12/12/12), and tumor growth is shown ( o ). The depletion of <t>CSF1R</t> + cells is shown ( p-q ). *: P<0.05; **: P<0.01; ***: P<0.005; ****: P<0.001 based on two-tailed unpaired t tests ( b-l, n, p and q ); Two-way ANOVA ( m and o ); All error bars represent the S.E.M. of technical replicates. Data are representative of two independent experiments ( a-q ).
Anti Mouse Csf1r, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mouse csf1r/product/Bio X Cell
Average 96 stars, based on 1 article reviews
anti mouse csf1r - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
anti-mouse csf1r monoclonal antibody afs98 be0213  (Fisher Scientific)
90
Fisher Scientific anti-mouse csf1r monoclonal antibody afs98 be0213

Anti Mouse Csf1r Monoclonal Antibody Afs98 Be0213, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-mouse csf1r monoclonal antibody afs98 be0213/product/Fisher Scientific
Average 90 stars, based on 1 article reviews
anti-mouse csf1r monoclonal antibody afs98 be0213 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


a-e. Flow cytometry analysis the proportions of CD4 + T and CD8 + T cells of MC38 (n=13/12), B16 (n=13/13), ID8 (n=11/12) and LLC (n=13/13) tumor microenvironments following control mAb or anti-hCD209 mAb treatment. f-i. Flow cytometry analysis of the proportions of CD4 + IFN-γ + T cells and CD8 + IFN-γ + T cells in the MC38, B16, ID8 and LLC tumor microenvironments following control mAb or anti-hCD209 mAb treatment. j-l. The expression levels of IFN-γ in the tumor culture supernatant and mouse serum of MC38, LLC, B16 and ID8 tumor-bearing mice after control mAb or anti-hCD209 mAb treatment were detected via ELISA. m. MC38 tumors were subcutaneously implanted into hCD209-KI mice, followed by anti-control, anti-hCD209 mAb, anti-control+αCD8 or anti-hCD209+αCD8 treatment (n=12/12/12/12), and tumor growth is shown ( m ). The depletion of CD8+ T cells is shown ( n ). o-q. Tumors were implanted as described in m , followed by treatment with anti-control, anti-hCD209 mAb, anti-control+αCSF1R or anti-hCD209+αCSF1R (n=12/12/12/12), and tumor growth is shown ( o ). The depletion of CSF1R + cells is shown ( p-q ). *: P<0.05; **: P<0.01; ***: P<0.005; ****: P<0.001 based on two-tailed unpaired t tests ( b-l, n, p and q ); Two-way ANOVA ( m and o ); All error bars represent the S.E.M. of technical replicates. Data are representative of two independent experiments ( a-q ).

Journal: bioRxiv

Article Title: Myeloid CD209 impairs T-cell activation by inducing ICAM-2–ERM–dependent cortical stiffening

doi: 10.64898/2026.01.19.699861

Figure Lengend Snippet: a-e. Flow cytometry analysis the proportions of CD4 + T and CD8 + T cells of MC38 (n=13/12), B16 (n=13/13), ID8 (n=11/12) and LLC (n=13/13) tumor microenvironments following control mAb or anti-hCD209 mAb treatment. f-i. Flow cytometry analysis of the proportions of CD4 + IFN-γ + T cells and CD8 + IFN-γ + T cells in the MC38, B16, ID8 and LLC tumor microenvironments following control mAb or anti-hCD209 mAb treatment. j-l. The expression levels of IFN-γ in the tumor culture supernatant and mouse serum of MC38, LLC, B16 and ID8 tumor-bearing mice after control mAb or anti-hCD209 mAb treatment were detected via ELISA. m. MC38 tumors were subcutaneously implanted into hCD209-KI mice, followed by anti-control, anti-hCD209 mAb, anti-control+αCD8 or anti-hCD209+αCD8 treatment (n=12/12/12/12), and tumor growth is shown ( m ). The depletion of CD8+ T cells is shown ( n ). o-q. Tumors were implanted as described in m , followed by treatment with anti-control, anti-hCD209 mAb, anti-control+αCSF1R or anti-hCD209+αCSF1R (n=12/12/12/12), and tumor growth is shown ( o ). The depletion of CSF1R + cells is shown ( p-q ). *: P<0.05; **: P<0.01; ***: P<0.005; ****: P<0.001 based on two-tailed unpaired t tests ( b-l, n, p and q ); Two-way ANOVA ( m and o ); All error bars represent the S.E.M. of technical replicates. Data are representative of two independent experiments ( a-q ).

Article Snippet: The human IgG4 isotype control (clone R1, (Selleck Cat# A2052, RRID: AB_3713065)), anti-mouse PD-1 (clone RMP1-14, (Selleck Cat# A2122, RRID:AB_3644244)), anti-mouse CD8a (clone 2.43, (Selleck Cat# A2102, RRID:AB_3099521)), and anti-mouse CSF1R (clone AFS98, (Bio X Cell Cat# BE0213, RRID:AB_2687699)).

Techniques: Flow Cytometry, Control, Expressing, Enzyme-linked Immunosorbent Assay, Two Tailed Test

Journal: iScience

Article Title: Macrophage recruitment in immune-privileged lens during capsule repair, necrotic fiber removal, and fibrosis

doi: 10.1016/j.isci.2021.102533

Figure Lengend Snippet:

Article Snippet: Anti-mouse CSF1R (AFS98, BE0213) monoclonal antibody was obtained from Fisher Scientific (Pittsburgh, PA, USA).

Techniques: Recombinant, Double Knockout, Knock-Out, Software